.svg)
.svg)
.svg)
.svg){kind=icon}
.svg)
.svg){kind=icon}
.svg)
.svg){kind=icon}
.svg)
.svg){kind=icon}
.svg){kind=icon}
.svg){kind=icon}
Publication date: Jan. 31, 2024
- Year of incorporation: 1865
- Year added to EUROSTOXX 50: 1998
- Highest price ever: € 144.20 in April 2015
- Average trading volume: Approximately 3.1 million shares per day
- Price performance over the past 12 months: - 27,4 %
Introduction about the company
Bayer AG is a leading global company in the pharmaceutical and chemical industries, headquartered in Leverkusen, Germany. Operating in more than 100 countries, Bayer provides innovative solutions in healthcare, agriculture and biological sciences. With strong brands such as Aspirin and Roundup, Bayer is a trusted name in both the medical and agricultural sectors.
Key figures & performance
In 2024, Bayer achieved sales of €46.73 billion and net profits of €1.89 billion. The company has more than 99,000 employees worldwide and continues to invest heavily in research and development each year, with a budget of about €5.4 billion in 2024. Bayer's market capitalization was €21.15 billion in January 2025, keeping it a major player in the global health and agriculture sector.
History & development
Bayer was founded in 1863 and has since established a leading position in the chemical and pharmaceutical industries. The company introduced pioneering products such as Aspirin, which was patented in 1899. Through strategic acquisitions, such as the 2018 acquisition of Monsanto, Bayer has expanded its portfolio to include seeds and crop protection products. Although the Monsanto deal exposed the company to legal risks, Bayer remains focused on innovative solutions in both healthcare and agriculture.
Still, the company is facing major issues surrounding Roundup, a controversial herbicide produced by the company and introduced through its acquisition of Monsanto. There are many lawsuits and discussions around the world about this product, particularly because of claims that the active ingredient glyphosate may be carcinogenic. In the United States, thousands of people have sued Bayer because they believe exposure to Roundup has caused lymphoma.
Industry & competition
Bayer operates in the competitive markets of pharmaceuticals and agriculture, competing with companies such as Novartis, BASF and Syngenta. The company is distinguished by a broad product range and a strong global presence. In addition, Bayer is investing heavily in technologies for more sustainable agriculture and in medicines that enable life-saving treatments.
Bayer's influence on the EURO STOXX 50
Bayer has a weighting of 0.54% in the EURO STOXX 50 (measured in December 2024) and thus has a very small influence on the index. Bayer's share price is influenced by factors such as global demand for drugs and agricultural products, legal issues and economic trends.
Investment analysis & outlook
Below you can see Bayer's share price performance compared to the EURO STOXX 50 over the past five years. While the index achieved a price performance of +42.55%, Bayer showed a loss of - 71.19%. This reflects the impact of legal settlements and costs arising from the Monsanto acquisition, as well as disappointing results in certain divisions.
Bayer's negative share price performance is attributed to ongoing legal challenges surrounding Roundup, rising costs in pharmaceutical production, and headwinds in global agricultural markets. The legal settlements have cost the company billions, eroding investor confidence. However, Bayer continues to invest in new drugs and sustainable agricultural solutions to restore its profitability and market share.
News & updates
Bayer recently announced a €2 billion investment in research into new cancer drugs and genetic solutions for crop protection. In addition, the company is focusing on the development of biodegradable crop protection products and innovative drugs against chronic diseases.
With a strong focus on research and sustainability, Bayer remains committed to recovery and growth. The success of this strategy will depend on its ability to minimize legal risks and capitalize on market opportunities in the health and agriculture sectors. For more information about this company, please visit: www.bayer.com.
Disclaimer: Investing involves risk. Our analysts are not financial advisors. Always consult an advisor when making financial decisions. The information and tips provided on this website are based on our analysts' own insights and experiences. They are therefore for educational purposes only.
.webp)
.webp)
.webp)
